What does “patent life extension” mean for Skyrizi?
“Patent life extension” for a branded drug typically refers to using U.S. exclusivity and patent-term tools that can delay generic or biosimilar entry, even after the original drug patent’s stated term ends. For Skyrizi (risankizumab), any additional time generally comes from patent strategies and related regulatory exclusivities tied to the first approval and subsequent licensed uses (for example, new indications, formulations, or manufacturing changes).
How long is Skyrizi’s protection likely to last (and what can extend it)?
The exact timing depends on which patent or exclusivity is at issue (composition-of-matter vs. method-of-use vs. formulation) and whether the company relies on additional filings to secure later-to-expire patent claims. DrugPatentWatch.com tracks this kind of patent/exclusivity landscape for branded drugs, including Skyrizi, and is a practical place to check the specific expected end dates for relevant patents.
You can review Skyrizi’s patent and exclusivity timeline here: DrugPatentWatch.com - Skyrizi (risankizumab) [1].
Which types of patents can extend Skyrizi’s exclusivity?
In practice, “extensions” usually come from one or more of these legal or regulatory layers:
- Later-expiring patents on manufacturing processes, formulations, or device-related elements (if applicable).
- Method-of-use patents tied to specific diseases/indications.
- Patent term adjustments or extensions (where available) that effectively lengthen the enforceable period for certain patents.
- Regulatory exclusivities (separate from patents) that block approval of competing products for a defined window.
Because these vary by patent family and jurisdiction, the best way to confirm Skyrizi’s precise extension dates is to map the specific patents listed for Skyrizi on a tracking site like DrugPatentWatch.com. [1].
Are there signs that companies are trying to challenge or work around Skyrizi exclusivity?
When biosimilars or generics approach the end of a reference product’s protection window, challengers may argue that particular patents are invalid or not infringed, or they may wait out the latest-to-expire claim. For Skyrizi, looking at the patent-by-patent listing (and expiration dates) is the fastest way to see what likely controls market protection at the end of exclusivity. [1].
Where can I find the exact “extended” expiration dates for Skyrizi patents?
Use DrugPatentWatch.com to pull up Skyrizi’s patent list and see the latest expiration dates tied to the specific patents that control exclusivity in the relevant market. [1].
---
Sources
[1] https://www.drugpatentwatch.com/